Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNYSE:BVSNASDAQ:CVRXNASDAQ:EMBC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.08+2.1%$12.45$11.68▼$25.36$556.27M1.12382,011 shs16,453 shsBVSBioventus$6.94+1.8%$6.71$5.73▼$14.38$569.26M0.84429,787 shs34,886 shsCVRXCVRx$6.84+3.7%$6.42$4.30▼$18.55$177.02M1.23316,090 shs9,690 shsEMBCEmbecta$10.30+2.7%$10.87$9.20▼$21.48$602.55M1.08496,481 shs13,169 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL-3.89%-3.10%-4.51%-4.02%-38.56%BVSBioventus-4.54%+3.02%+1.94%-10.85%+16.98%CVRXCVRx+0.15%+12.07%+0.46%+6.29%-46.73%EMBCEmbecta-2.81%+3.51%+2.45%-12.78%-12.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICALN/AN/AN/AN/AN/AN/AN/AN/ABVSBioventus2.7464 of 5 stars3.40.00.00.00.04.21.3CVRXCVRx2.7329 of 5 stars3.41.00.00.02.14.20.6EMBCEmbecta4.129 of 5 stars3.21.03.30.00.03.33.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/ABVSBioventus 2.75Moderate Buy$13.7598.13% UpsideCVRXCVRx 2.71Moderate Buy$14.50112.14% UpsideEMBCEmbecta 2.33Hold$19.3387.70% UpsideCurrent Analyst Ratings BreakdownLatest CVRX, AVNS, EMBC, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/8/2025CVRXCVRxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/8/2025CVRXCVRxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.81$11.62 per share1.04$18.03 per share0.67BVSBioventus$567.70M1.00$0.55 per share12.58$2.80 per share2.48CVRXCVRx$51.29M3.47N/AN/A$2.93 per share2.33EMBCEmbecta$1.08B0.56$3.33 per share3.09($12.80) per share-0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.37N/A6.98N/A-55.80%6.26%4.63%7/30/2025 (Estimated)BVSBioventus-$156.23M-$0.48N/A15.09N/A-7.11%15.61%4.01%N/ACVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)EMBCEmbecta$78.30M$0.9011.463.360.664.89%-19.67%12.27%8/8/2025 (Estimated)Latest CVRX, AVNS, EMBC, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025CVRXCVRx-$0.52N/AN/AN/AN/AN/A7/30/2025Q2 2025AVNSAVANOS MEDICAL$0.18N/AN/AN/A$165.50 millionN/A5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/AEMBCEmbecta$0.605.83%N/A66.67%N/ALatest CVRX, AVNS, EMBC, and BVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56BVSBioventus1.851.410.99CVRXCVRx0.7114.8213.45EMBCEmbectaN/A2.481.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%BVSBioventus62.94%CVRXCVRx75.27%EMBCEmbecta93.83%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%BVSBioventus33.00%CVRXCVRx18.90%EMBCEmbecta0.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableCVRXCVRx16026.07 million21.15 millionOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableCVRX, AVNS, EMBC, and BVS HeadlinesRecent News About These CompaniesEmbecta Corp. (EMBC) Lowered FY25 Guidance Amid Foreign Exchange ChallengesJune 27, 2025 | finance.yahoo.comEmbecta (NASDAQ:EMBC) Sets New 1-Year Low - Here's What HappenedJune 27, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Stock Price Down 3.7% - What's Next?June 26, 2025 | marketbeat.comEmbecta Corp. (EMBC) Lowered FY25 Guidance Amid Foreign Exchange ChallengesJune 26, 2025 | insidermonkey.comEmbecta (NASDAQ:EMBC) Sets New 1-Year Low - Should You Sell?June 16, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Hits New 12-Month Low - Here's WhyJune 9, 2025 | marketbeat.comembecta to Participate in Investor EventsMay 27, 2025 | globenewswire.comIndependent Non-Executive Chairman of Embecta Picks Up 13% More StockMay 25, 2025 | finance.yahoo.comDavid F. Melcher Purchases 10,000 Shares of Embecta Corp. (NASDAQ:EMBC) StockMay 24, 2025 | insidertrades.comEmbecta eyes shift from insulin delivery to broader medical supplies focusMay 22, 2025 | drugdeliverybusiness.comDembecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor DayMay 22, 2025 | globenewswire.comEmbecta: Not Nearly As Cheap As The 4x Forward P/E Ratio Would ImplyMay 15, 2025 | seekingalpha.comEmbecta Corp. (NASDAQ:EMBC) Q2 2025 Earnings Call TranscriptMay 10, 2025 | msn.comEmbecta Corp (EMBC) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue DeclineMay 10, 2025 | finance.yahoo.comEmbecta raises adjusted EBITDA margin outlook for FY 2025 amid restructuring and debt reductionMay 10, 2025 | msn.comEMBECTA Earnings Preview: Recent $EMBC Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comEmbecta Corp. (EMBC) Q2 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comEmbecta beats Q2 expectations, maintains full-year EPS outlookMay 9, 2025 | investing.comEmbecta to undergo further restructuring, lowers guidance amid tariff impactMay 9, 2025 | drugdeliverybusiness.comDIs Now An Opportune Moment To Examine Embecta Corp. (NASDAQ:EMBC)?May 9, 2025 | finance.yahoo.comEmbecta Corp. 2025 Q2 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVRX, AVNS, EMBC, and BVS Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.08 +0.25 (+2.13%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Bioventus NYSE:BVS$6.94 +0.12 (+1.76%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.CVRx NASDAQ:CVRX$6.84 +0.25 (+3.72%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Embecta NASDAQ:EMBC$10.30 +0.27 (+2.69%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
